[ET Net News Agency, 6 January 2021] Daiwa Research lifted its target price for Wuxi
Biologics Cayman (02269) to HK$118 from HK$100 and maintained its "buy" rating.
The research house said cited WuXi in Daiwa PURE Energy and Healthcare Virtual
Conference on 5 January saying that the newly-acquired facilities from Bayer are expected
to contribute annual revenue of CNY500-800m.
Wuxi now owns full manufacturing facilities for both drug substance (DS) and drug
product (DP) in Europe and will be better prepared to meet the demand for COVID-19-related
vaccines and neutralising antibodies with an estimated total backlog of US$1bn, Daiwa
believes.
Daiwa raised its 2021 revenue by 5.4% and 2022 revenue by 8.8%. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02269 WUXI BIO
Nominal 
12.620 -0.620 (-4.683%) Research Report
06/01/2021 11:27
{I-bank focus}Daiwa lifts Wuxi Biologics (02269) to HK$118
| Remark: | Real time quote last updated: 19/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |